In the next year or two, MDMA will become the first psychedelic drug to be approved as a psychiatric medication by the FDA in the United States. This has been made possible by the perseverance of Rick Doblin and his long-time organisation, MAPS, which has spent years and hundreds of millions of dollars on scientific studies to prove that this molecule, known on the street as “ecstasy“, is effective in the treatment of post-traumatic stress disorder, among other promising applications. Twenty-five years ago, in the late 1990s, a pioneering study carried out in Spain reached (or,...